ID   ASAH1_HUMAN             Reviewed;         395 AA.
AC   Q13510; E9PDS0; Q6W898; Q96AS2;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2009, sequence version 5.
DT   10-MAY-2017, entry version 176.
DE   RecName: Full=Acid ceramidase;
DE            Short=AC;
DE            Short=ACDase;
DE            Short=Acid CDase;
DE            EC=3.5.1.23 {ECO:0000269|PubMed:7744740};
DE   AltName: Full=Acylsphingosine deacylase;
DE   AltName: Full=N-acylsphingosine amidohydrolase;
DE   AltName: Full=Putative 32 kDa heart protein;
DE            Short=PHP32;
DE   Contains:
DE     RecName: Full=Acid ceramidase subunit alpha;
DE   Contains:
DE     RecName: Full=Acid ceramidase subunit beta;
DE   Flags: Precursor;
GN   Name=ASAH1; Synonyms=ASAH; ORFNames=HSD-33, HSD33;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE,
RP   VARIANT FRBRL LYS-222, AND VARIANTS MET-72; VAL-93 AND ALA-246.
RC   TISSUE=Fibroblast, Pituitary, and Urine;
RX   PubMed=8955159; DOI=10.1074/jbc.271.51.33110;
RA   Koch J., Gaertner S., Li C.M., Quintern L.E., Bernardo K., Levran O.,
RA   Schnabel D., Desnick R.J., Schuchman E.H., Sandhoff K.;
RT   "Molecular cloning and characterization of a full-length complementary
RT   DNA encoding human acid ceramidase. Identification of the first
RT   molecular lesion causing Farber disease.";
RL   J. Biol. Chem. 271:33110-33115(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS MET-72; VAL-93
RP   AND ALA-246.
RA   Churchill J.R., Wieland S.J., Hoffman S., Gallin E.K., Murphy P.M.;
RT   "A new gene family predicted by a novel human heart cDNA.";
RL   Mol. Biol. Cell 6:418-418(1995).
RN   [3]
RP   SEQUENCE REVISION.
RA   Wieland S.J., Hoffman S., Churchill J.R., Gallin E.K., Murphy P.M.;
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RA   Fan M.M., Miao S.Y., Zhang X.D., Qiao Y., Liang G., Wang L.F.;
RT   "A new spermatogenesis related gene.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS FRBRL HIS-22; ASP-23;
RP   VAL-138; LYS-222 AND ASP-320, AND VARIANTS MET-72; VAL-93 AND ALA-246.
RX   PubMed=10993717; DOI=10.1006/mgme.2000.3029;
RA   Zhang Z., Mandal A.K., Mital A., Popescu N., Zimonjic D., Moser A.,
RA   Moser H., Mukherjee A.B.;
RT   "Human acid ceramidase gene: novel mutations in Farber disease.";
RL   Mol. Genet. Metab. 70:301-309(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS FRBRL VAL-138; GLY-254
RP   AND ARG-362.
RX   PubMed=10610716; DOI=10.1006/geno.1999.5940;
RA   Li C.M., Park J.H., He X., Levy B., Chen F., Arai K., Adler D.A.,
RA   Disteche C.M., Koch J., Sandhoff K., Schuchman E.H.;
RT   "The human acid ceramidase gene (ASAH): structure, chromosomal
RT   location, mutation analysis, and expression.";
RL   Genomics 62:223-231(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND
RP   VARIANTS MET-72; VAL-93 AND ALA-246.
RC   TISSUE=Bone marrow, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   SUBUNIT.
RX   PubMed=7744740; DOI=10.1074/jbc.270.19.11098;
RA   Bernardo K., Hurwitz R., Zenk T., Desnick R.J., Ferlinz K.,
RA   Schuchman E.H., Sandhoff K.;
RT   "Purification, characterization, and biosynthesis of human acid
RT   ceramidase.";
RL   J. Biol. Chem. 270:11098-11102(1995).
RN   [10]
RP   GLYCOSYLATION AT ASN-259 AND ASN-286.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-259.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-259.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-259 AND ASN-286.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   VARIANTS FRBRL CYS-36 AND ASP-320.
RX   PubMed=11241842; DOI=10.1002/humu.5;
RA   Bar J., Linke T., Ferlinz K., Neumann U., Schuchman E.H., Sandhoff K.;
RT   "Molecular analysis of acid ceramidase deficiency in patients with
RT   Farber disease.";
RL   Hum. Mutat. 17:199-209(2001).
RN   [18]
RP   VARIANTS FRBRL VAL-96 DEL; GLU-97 AND ARG-235, AND VARIANT ILE-369.
RX   PubMed=12638942; DOI=10.1023/A:1022047408477;
RA   Muramatsu T., Sakai N., Yanagihara L., Yamada M., Nishigaki T.,
RA   Kokubu C., Tsukamoto H., Ito M., Inui K.;
RT   "Mutation analysis of the acid ceramidase gene in Japanese patients
RT   with Farber disease.";
RL   J. Inherit. Metab. Dis. 25:585-592(2002).
RN   [19]
RP   VARIANT FRBRL VAL-182.
RX   PubMed=16951918; DOI=10.1007/s10038-006-0019-z;
RA   Devi A.R.R., Gopikrishna M., Ratheesh R., Savithri G., Swarnalata G.,
RA   Bashyam M.;
RT   "Farber lipogranulomatosis: clinical and molecular genetic analysis
RT   reveals a novel mutation in an Indian family.";
RL   J. Hum. Genet. 51:811-814(2006).
RN   [20]
RP   VARIANT FRBRL TRP-168.
RX   PubMed=20609603; DOI=10.1016/j.ejpn.2010.06.002;
RA   Cvitanovic-Sojat L., Gjergja Juraski R., Sabourdy F., Fensom A.H.,
RA   Fumic K., Paschke E., Levade T.;
RT   "Farber lipogranulomatosis type 1--late presentation and early death
RT   in a Croatian boy with a novel homozygous ASAH1 mutation.";
RL   Eur. J. Paediatr. Neurol. 15:171-173(2011).
RN   [21]
RP   VARIANT SMAPME MET-42, AND CHARACTERIZATION OF VARIANT SMAPME MET-42.
RX   PubMed=22703880; DOI=10.1016/j.ajhg.2012.05.001;
RA   Zhou J., Tawk M., Tiziano F.D., Veillet J., Bayes M., Nolent F.,
RA   Garcia V., Servidei S., Bertini E., Castro-Giner F., Renda Y.,
RA   Carpentier S., Andrieu-Abadie N., Gut I., Levade T., Topaloglu H.,
RA   Melki J.;
RT   "Spinal muscular atrophy associated with progressive myoclonic
RT   epilepsy is caused by mutations in ASAH1.";
RL   Am. J. Hum. Genet. 91:5-14(2012).
RN   [22]
RP   VARIANT FRBRL GLY-97.
RX   PubMed=21893389; DOI=10.1016/j.braindev.2011.07.003;
RA   Chedrawi A.K., Al-Hassnan Z.N., Al-Muhaizea M., Colak D.,
RA   Al-Younes B., Albakheet A., Tulba S., Kaya N.;
RT   "Novel V97G ASAH1 mutation found in Farber disease patients: unique
RT   appearance of the disease with an intermediate severity, and marked
RT   early involvement of central and peripheral nervous system.";
RL   Brain Dev. 34:400-404(2012).
RN   [23]
RP   VARIANTS FRBRL ARG-185 AND GLN-382 (ISOFORM 2).
RX   PubMed=21982811; DOI=10.1016/j.braindev.2011.09.006;
RA   Al Jasmi F.;
RT   "A novel mutation in an atypical presentation of the rare infantile
RT   Farber disease.";
RL   Brain Dev. 34:533-535(2012).
RN   [24]
RP   VARIANT SMAPME ASN-152.
RX   PubMed=24164096; DOI=10.1111/cge.12307;
RG   FORGE Canada Consortium;
RA   Dyment D.A., Sell E., Vanstone M.R., Smith A.C., Garandeau D.,
RA   Garcia V., Carpentier S., Le Trionnaire E., Sabourdy F.,
RA   Beaulieu C.L., Schwartzentruber J.A., McMillan H.J., Majewski J.,
RA   Bulman D.E., Levade T., Boycott K.M.;
RT   "Evidence for clinical, genetic and biochemical variability in spinal
RT   muscular atrophy with progressive myoclonic epilepsy.";
RL   Clin. Genet. 86:558-563(2014).
CC   -!- FUNCTION: Hydrolyzes the sphingolipid ceramide into sphingosine
CC       and free fatty acid. {ECO:0000269|PubMed:7744740}.
CC   -!- CATALYTIC ACTIVITY: N-acylsphingosine + H(2)O = a carboxylate +
CC       sphingosine. {ECO:0000269|PubMed:7744740}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=149 uM for N-lauroylsphingosine {ECO:0000269|PubMed:7744740};
CC         Vmax=136 nmol/h/mg enzyme with N-lauroylsphingosine as substrate
CC         {ECO:0000269|PubMed:7744740};
CC       pH dependence:
CC         Optimum pH is 3.8-4.3 with N-lauroylsphingosine as substrate.
CC         {ECO:0000269|PubMed:7744740};
CC   -!- SUBUNIT: Heterodimer of one alpha and one beta subunit.
CC       {ECO:0000269|PubMed:7744740}.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q13510-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13510-2; Sequence=VSP_037504;
CC         Note=Variant in position: 185:W->R (in FL). Variant in position:
CC         382:K->Q (in FL). {ECO:0000269|PubMed:21982811};
CC       Name=3;
CC         IsoId=Q13510-3; Sequence=VSP_037504, VSP_046284, VSP_046285;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Broadly expressed with highest expression in
CC       heart.
CC   -!- DISEASE: Farber lipogranulomatosis (FRBRL) [MIM:228000]: An
CC       autosomal recessive lysosomal storage disorder characterized by
CC       subcutaneous lipid-loaded nodules, excruciating pain in the joints
CC       and extremities, and marked accumulation of ceramide in lysosomes.
CC       Disease severity is variable. The most severe disease subtype is a
CC       rare neonatal form with death occurring before 1 year of age.
CC       {ECO:0000269|PubMed:10610716, ECO:0000269|PubMed:10993717,
CC       ECO:0000269|PubMed:11241842, ECO:0000269|PubMed:12638942,
CC       ECO:0000269|PubMed:16951918, ECO:0000269|PubMed:20609603,
CC       ECO:0000269|PubMed:21893389, ECO:0000269|PubMed:21982811,
CC       ECO:0000269|PubMed:8955159}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spinal muscular atrophy with progressive myoclonic
CC       epilepsy (SMAPME) [MIM:159950]: An autosomal recessive
CC       neuromuscular disorder characterized by childhood onset of motor
CC       deficits and progressive myoclonic seizures, after normal
CC       developmental milestones. Proximal muscle weakness and generalized
CC       muscular atrophy are due to degeneration of spinal motor neurons.
CC       Myoclonic epilepsy is generally resistant to conventional therapy.
CC       The disease course is progressive and leads to respiratory muscle
CC       involvement and severe handicap or early death from respiratory
CC       insufficiency. {ECO:0000269|PubMed:22703880,
CC       ECO:0000269|PubMed:24164096}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the acid ceramidase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC73009.1; Type=Frameshift; Positions=15, 21; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U70063; AAC50907.1; -; mRNA.
DR   EMBL; U47674; AAC73009.1; ALT_FRAME; mRNA.
DR   EMBL; AY305384; AAQ75550.1; -; mRNA.
DR   EMBL; AF220175; AAF91230.1; -; Genomic_DNA.
DR   EMBL; AF220172; AAF91230.1; JOINED; Genomic_DNA.
DR   EMBL; AF220173; AAF91230.1; JOINED; Genomic_DNA.
DR   EMBL; AC124242; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC016481; AAH16481.1; -; mRNA.
DR   EMBL; BC016828; AAH16828.1; -; mRNA.
DR   CCDS; CCDS47813.1; -. [Q13510-3]
DR   CCDS; CCDS6005.1; -. [Q13510-2]
DR   CCDS; CCDS6006.1; -. [Q13510-1]
DR   RefSeq; NP_001120977.1; NM_001127505.2. [Q13510-3]
DR   RefSeq; NP_004306.3; NM_004315.5. [Q13510-2]
DR   RefSeq; NP_808592.2; NM_177924.4. [Q13510-1]
DR   UniGene; Hs.527412; -.
DR   UniGene; Hs.633993; -.
DR   ProteinModelPortal; Q13510; -.
DR   BioGrid; 106920; 32.
DR   IntAct; Q13510; 7.
DR   MINT; MINT-1368026; -.
DR   STRING; 9606.ENSP00000371152; -.
DR   BindingDB; Q13510; -.
DR   ChEMBL; CHEMBL5463; -.
DR   SwissLipids; SLP:000000162; -.
DR   MEROPS; C89.001; -.
DR   iPTMnet; Q13510; -.
DR   PhosphoSitePlus; Q13510; -.
DR   SwissPalm; Q13510; -.
DR   BioMuta; ASAH1; -.
DR   DMDM; 239938949; -.
DR   EPD; Q13510; -.
DR   MaxQB; Q13510; -.
DR   PaxDb; Q13510; -.
DR   PeptideAtlas; Q13510; -.
DR   PRIDE; Q13510; -.
DR   TopDownProteomics; Q13510-1; -. [Q13510-1]
DR   DNASU; 427; -.
DR   Ensembl; ENST00000262097; ENSP00000262097; ENSG00000104763. [Q13510-1]
DR   Ensembl; ENST00000314146; ENSP00000326970; ENSG00000104763. [Q13510-3]
DR   Ensembl; ENST00000381733; ENSP00000371152; ENSG00000104763. [Q13510-2]
DR   Ensembl; ENST00000635998; ENSP00000490506; ENSG00000104763. [Q13510-1]
DR   Ensembl; ENST00000637790; ENSP00000490272; ENSG00000104763. [Q13510-1]
DR   GeneID; 427; -.
DR   KEGG; hsa:427; -.
DR   UCSC; uc003wyl.3; human. [Q13510-1]
DR   CTD; 427; -.
DR   DisGeNET; 427; -.
DR   GeneCards; ASAH1; -.
DR   HGNC; HGNC:735; ASAH1.
DR   HPA; HPA005468; -.
DR   MalaCards; ASAH1; -.
DR   MIM; 159950; phenotype.
DR   MIM; 228000; phenotype.
DR   MIM; 613468; gene.
DR   neXtProt; NX_Q13510; -.
DR   OpenTargets; ENSG00000104763; -.
DR   Orphanet; 333; Farber lipogranulomatosis.
DR   Orphanet; 2590; Hereditary myoclonus - progressive distal muscular atrophy.
DR   PharmGKB; PA35025; -.
DR   eggNOG; ENOG410IFSS; Eukaryota.
DR   eggNOG; ENOG410XQ6Y; LUCA.
DR   GeneTree; ENSGT00530000063548; -.
DR   HOGENOM; HOG000007253; -.
DR   HOVERGEN; HBG050586; -.
DR   InParanoid; Q13510; -.
DR   KO; K12348; -.
DR   OMA; WYTINLD; -.
DR   OrthoDB; EOG091G08N9; -.
DR   PhylomeDB; Q13510; -.
DR   TreeFam; TF313219; -.
DR   BRENDA; 3.5.1.23; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; Q13510; -.
DR   ChiTaRS; ASAH1; human.
DR   GeneWiki; ASAH1; -.
DR   GenomeRNAi; 427; -.
DR   PRO; PR:Q13510; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000104763; -.
DR   CleanEx; HS_ASAH1; -.
DR   ExpressionAtlas; Q13510; baseline and differential.
DR   Genevisible; Q13510; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0017040; F:ceramidase activity; TAS:Reactome.
DR   GO; GO:0006672; P:ceramide metabolic process; TAS:ProtInc.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   InterPro; IPR016699; Acid_ceramidase-like.
DR   InterPro; IPR029130; Acid_ceramidase_N.
DR   InterPro; IPR029132; CBAH/NAAA_C.
DR   Pfam; PF02275; CBAH; 1.
DR   Pfam; PF15508; NAAA-beta; 1.
DR   PIRSF; PIRSF017632; Acid_ceramidase-like; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Epilepsy; Glycoprotein; Hydrolase; Lysosome;
KW   Neurodegeneration; Polymorphism; Reference proteome; Signal.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    142       Acid ceramidase subunit alpha.
FT                                /FTId=PRO_0000002312.
FT   CHAIN       143    395       Acid ceramidase subunit beta.
FT                                /FTId=PRO_0000002313.
FT   CARBOHYD    173    173       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    195    195       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    259    259       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    286    286       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    342    342       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    348    348       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     26       MPGRSCVALVLLAAAVSCAVAQHAPP -> MNCCIGLGEKA
FT                                RGSHRASYPSLSALFTEASILGFGSFAVKAQ (in
FT                                isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_037504.
FT   VAR_SEQ      42     42       T -> TVFPAVIR (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_046284.
FT   VAR_SEQ      73    101       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_046285.
FT   VARIANT      22     22       Q -> H (in FRBRL).
FT                                {ECO:0000269|PubMed:10993717}.
FT                                /FTId=VAR_038166.
FT   VARIANT      23     23       H -> D (in FRBRL).
FT                                {ECO:0000269|PubMed:10993717}.
FT                                /FTId=VAR_038167.
FT   VARIANT      36     36       Y -> C (in FRBRL; dbSNP:rs137853595).
FT                                {ECO:0000269|PubMed:11241842}.
FT                                /FTId=VAR_021579.
FT   VARIANT      42     42       T -> M (in SMAPME; results in reduced
FT                                activity; dbSNP:rs145873635).
FT                                {ECO:0000269|PubMed:22703880}.
FT                                /FTId=VAR_068722.
FT   VARIANT      70     70       A -> V (in dbSNP:rs10103355).
FT                                /FTId=VAR_057979.
FT   VARIANT      72     72       V -> M (in dbSNP:rs1071645).
FT                                {ECO:0000269|PubMed:10993717,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8955159,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_008860.
FT   VARIANT      88     88       V -> M (in dbSNP:rs1071645).
FT                                /FTId=VAR_057980.
FT   VARIANT      93     93       I -> V (in dbSNP:rs1049874).
FT                                {ECO:0000269|PubMed:10993717,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8955159,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_008861.
FT   VARIANT      96     96       Missing (in FRBRL).
FT                                {ECO:0000269|PubMed:12638942}.
FT                                /FTId=VAR_021580.
FT   VARIANT      97     97       V -> E (in FRBRL).
FT                                {ECO:0000269|PubMed:12638942}.
FT                                /FTId=VAR_021581.
FT   VARIANT      97     97       V -> G (in FRBRL).
FT                                {ECO:0000269|PubMed:21893389}.
FT                                /FTId=VAR_071994.
FT   VARIANT     124    124       D -> E (in dbSNP:rs2472205).
FT                                /FTId=VAR_038168.
FT   VARIANT     138    138       E -> V (in FRBRL; dbSNP:rs28934273).
FT                                {ECO:0000269|PubMed:10610716,
FT                                ECO:0000269|PubMed:10993717}.
FT                                /FTId=VAR_021582.
FT   VARIANT     152    152       K -> N (in SMAPME; results in reduced
FT                                activity; dbSNP:rs200455852).
FT                                {ECO:0000269|PubMed:24164096}.
FT                                /FTId=VAR_072247.
FT   VARIANT     168    168       G -> W (in FRBRL).
FT                                {ECO:0000269|PubMed:20609603}.
FT                                /FTId=VAR_071995.
FT   VARIANT     182    182       L -> V (in FRBRL; dbSNP:rs137853597).
FT                                {ECO:0000269|PubMed:16951918}.
FT                                /FTId=VAR_038169.
FT   VARIANT     222    222       T -> K (in FRBRL; dbSNP:rs137853593).
FT                                {ECO:0000269|PubMed:10993717,
FT                                ECO:0000269|PubMed:8955159}.
FT                                /FTId=VAR_008862.
FT   VARIANT     235    235       G -> R (in FRBRL).
FT                                {ECO:0000269|PubMed:12638942}.
FT                                /FTId=VAR_021583.
FT   VARIANT     246    246       V -> A (in dbSNP:rs10103355).
FT                                {ECO:0000269|PubMed:10993717,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8955159,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038170.
FT   VARIANT     254    254       R -> G (in FRBRL).
FT                                {ECO:0000269|PubMed:10610716}.
FT                                /FTId=VAR_021584.
FT   VARIANT     320    320       N -> D (in FRBRL; dbSNP:rs137853596).
FT                                {ECO:0000269|PubMed:10993717,
FT                                ECO:0000269|PubMed:11241842}.
FT                                /FTId=VAR_021585.
FT   VARIANT     362    362       P -> R (in FRBRL).
FT                                {ECO:0000269|PubMed:10610716}.
FT                                /FTId=VAR_021586.
FT   VARIANT     369    369       V -> I (in dbSNP:rs17636067).
FT                                {ECO:0000269|PubMed:12638942}.
FT                                /FTId=VAR_021587.
FT   CONFLICT    122    122       V -> A (in Ref. 4; AAQ75550).
FT                                {ECO:0000305}.
FT   CONFLICT    142    142       I -> V (in Ref. 8; AAH16828).
FT                                {ECO:0000305}.
FT   CONFLICT    155    155       L -> P (in Ref. 4; AAQ75550).
FT                                {ECO:0000305}.
FT   CONFLICT    233    233       Y -> N (in Ref. 4; AAQ75550).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       L -> P (in Ref. 4; AAQ75550).
FT                                {ECO:0000305}.
SQ   SEQUENCE   395 AA;  44660 MW;  83467DBE8917DB6D CRC64;
     MPGRSCVALV LLAAAVSCAV AQHAPPWTED CRKSTYPPSG PTYRGAVPWY TINLDLPPYK
     RWHELMLDKA PVLKVIVNSL KNMINTFVPS GKIMQVVDEK LPGLLGNFPG PFEEEMKGIA
     AVTDIPLGEI ISFNIFYELF TICTSIVAED KKGHLIHGRN MDFGVFLGWN INNDTWVITE
     QLKPLTVNLD FQRNNKTVFK ASSFAGYVGM LTGFKPGLFS LTLNERFSIN GGYLGILEWI
     LGKKDVMWIG FLTRTVLENS TSYEEAKNLL TKTKILAPAY FILGGNQSGE GCVITRDRKE
     SLDVYELDAK QGRWYVVQTN YDRWKHPFFL DDRRTPAKMC LNRTSQENIS FETMYDVLST
     KPVLNKLTVY TTLIDVTKGQ FETYLRDCPD PCIGW
//
